Follow
Bernard A Liu
Bernard A Liu
Pfizer, Gilead, Seagen, Broad Institute of Harvard & MIT, Lunenfeld Mount Sinai, UChicago, UC
Verified email at gilead.com
Title
Cited by
Cited by
Year
The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling
BA Liu, K Jablonowski, M Raina, M Arcé, T Pawson, PD Nash
Molecular cell 22, 851-868, 2006
3972006
Genome of Acanthamoeba castellanii highlights extensive lateral gene transfer and early evolution of tyrosine kinase signaling
M Clarke, AJ Lohan, B Liu, I Lagkouvardos, S Roy, N Zafar, C Bertelli, ...
Genome biology 14, 1-15, 2013
3352013
Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells
Y Peng, Q Kang, Q Luo, W Jiang, W Si, BA Liu, HH Luu, JK Park, X Li, ...
Journal of Biological Chemistry 279 (31), 32941-32949, 2004
2702004
High-throughput phosphotyrosine profiling using SH2 domains
K Machida, CM Thompson, K Dierck, K Jablonowski, S Kärkkäinen, B Liu, ...
Molecular cell 26 (6), 899-915, 2007
2022007
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
J Chen, S Jin, V Abraham, X Huang, B Liu, MJ Mitten, P Nimmer, X Lin, ...
Molecular cancer therapeutics 10 (12), 2340-2349, 2011
1982011
Molecular mechanisms of SH2-and PTB-domain-containing proteins in receptor tyrosine kinase signaling
MJ Wagner, MM Stacey, BA Liu, T Pawson
Cold Spring Harbor perspectives in biology 5 (12), a008987, 2013
1932013
Large-scale interaction profiling of PDZ domains through proteomic peptide-phage display using human and viral phage peptidomes
Y Ivarsson, R Arnold, M McLaughlin, S Nim, R Joshi, D Ray, B Liu, J Teyra, ...
Proceedings of the National Academy of Sciences 111 (7), 2542-2547, 2014
1662014
The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction
BA Liu, BW Engelmann, PD Nash
FEBS letters 586 (17), 2597-2605, 2012
1522012
SH2 domains recognize contextual peptide sequence information to determine selectivity
BA Liu, K Jablonowski, EE Shah, BW Engelmann, RB Jones, PD Nash
Molecular & Cellular Proteomics 9 (11), 2391-2404, 2010
1442010
The SH2 Domain-Containing Proteins in 21 Species Establish the Provenance and Scope of Phosphotyrosine Signaling in Eukaryotes
BA Liu, E Shah, K Jablonowski, A Stergachis, B Engelmann, PD Nash
Science Signaling 4 (202), ra83, 2011
1202011
Evolution of SH2 domains and phosphotyrosine signalling networks
BA Liu, PD Nash
Philosophical Transactions of the Royal Society B: Biological Sciences 367 …, 2012
932012
High‐throughput analysis of peptide‐binding modules
BA Liu, B Engelmann, PD Nash
Proteomics, 2012
622012
SRC Homology 2 Domain Binding Sites in Insulin, IGF-1 and FGF receptor mediated signaling networks reveal an extensive potential interactome
BA Liu, BW Engelmann, K Jablonowski, K Higginbotham, AB Stergachis, ...
Cell Communication and Signaling 10, 1-23, 2012
452012
Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers
BA Liu, D Olson, K Snead, J Gosink, EM Tenn, M Zaval, A Cao, D Sahetya, ...
Cancer Research 80 (16_Supplement), 5581-5581, 2020
242020
Selection of recombinant anti‐SH 3 domain antibodies by high‐throughput phage display
H Huang, NO Economopoulos, BA Liu, A Uetrecht, J Gu, N Jarvik, ...
Protein Science 24 (11), 1890-1900, 2015
172015
Introduction: History of SH2 domains and their applications
BA Liu, K Machida
SH2 Domains: Methods and Protocols, 3-35, 2017
112017
Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors
D Olson, P Younan, B Liu, G Blahnik-Fagan, J Gosink, K Snead, E Tenn, ...
Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022
92022
Expression and production of SH2 domain proteins
BA Liu, M Ogiue-Ikeda, K Machida
SH2 Domains: Methods and Protocols, 117-162, 2017
52017
Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle …
C Carosino, D Olson, K Snead, A Lee, L Farr, A Garg, C O'Day, ...
Cancer Research 82 (12_Supplement), 1140-1140, 2022
42022
Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications
K Klussman, EM Tenn, S Higgins, R Mazahreh, K Snead, J Hamilton, ...
Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020
42020
The system can't perform the operation now. Try again later.
Articles 1–20